Product Name :
KP136
Description:
KP136 (AL136) is an orally effective antiallergic agent. The IC50 is 76.1 μg/mL for histamine release and 63 ug/mL for degranulation.
CAS:
76239-32-2
Molecular Weight:
314.34
Formula:
C16H18N4O3
Chemical Name:
8-(hexyloxy)-3-(2H-1,2,3,4-tetrazol-5-yl)-2H-chromen-2-one
Smiles :
CCCCCCOC1C=CC=C2C=C(C(=O)OC=12)C1N=NNN=1
InChiKey:
GUIWTWATPUPDDY-UHFFFAOYSA-N
InChi :
InChI=1S/C16H18N4O3/c1-2-3-4-5-9-22-13-8-6-7-11-10-12(15-17-19-20-18-15)16(21)23-14(11)13/h6-8,10H,2-5,9H2,1H3,(H,17,18,19,20)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
KP136 (AL136) is an orally effective antiallergic agent. The IC50 is 76.1 μg/mL for histamine release and 63 ug/mL for degranulation.|Product information|CAS Number: 76239-32-2|Molecular Weight: 314.34|Formula: C16H18N4O3|Chemical Name: 8-(hexyloxy)-3-(2H-1,2,3,4-tetrazol-5-yl)-2H-chromen-2-one|Smiles: CCCCCCOC1C=CC=C2C=C(C(=O)OC=12)C1N=NNN=1|InChiKey: GUIWTWATPUPDDY-UHFFFAOYSA-N|InChi: InChI=1S/C16H18N4O3/c1-2-3-4-5-9-22-13-8-6-7-11-10-12(15-17-19-20-18-15)16(21)23-14(11)13/h6-8,10H,2-5,9H2,1H3,(H,17,18,19,20)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.Amivantamab JAK/STAT Signaling |Shelf Life: ≥12 months if stored properly.Plitidepsin site |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:32468618 |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|KP136 (0.01 μg/mL) inhibits this histamine release and degranulation in a dose-dependent manner, confirming that it is an inhibitor of mast cell activation. The IC50 is 76.1 μg/mL for histamine release and 63 ug/mL for degranulation.|In Vivo:|C4C at 0.2 mg/kg produces an equipotent effect to 1 mg/kg KP136 (KP-136) or 5 mg/kg DSCG. However, C4C is less effective by the oral route because it only produces a maximum inhibition of about 35% even at the high dose of 100 mg/kg, whereas KP136 shows an overt inhibitory effect of about 66% at the oral dose of 2 mg/kg. On the other hand, KP136 (1 mg/kg, i.v.) also remarkably inhibits 5-h homologous PCA, having an activity similar to that of C4C.|Products are for research use only. Not for human use.|
